Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 21, 2011

WaferGen and NuGEN to Co-Develop Products that Augment Gene- Expression Profiling

  • WaferGen Biosystems and NuGen Technologies will co-develop and co-market products for gene expression profiling and target enrichment. The aim is to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens such as FFPE tissue.

    The companies plan on conducting joint product development projects using both NuGen's sample-preparation and isothermal linear amplification (SPIA®) products and the WaferGen SmartChip Real-Time PCR System. The projects will focus on solutions for sample preparation, pre-amplification, and nucleic acid detection for gene expression and target enrichment from various sample types to drive speed and simplicity.

    SmartChip is designed to allow discovery and validation of biomarkers on a single platform. "This will expand the market potential of our SmartChip System by offering ready-to-go applications for biomarker discovery, validation, and screening," says Alnoor Shivji, chairman and CEO of WaferGen. He states that the two companies can offer a simple and straightforward workflow solution for single-cell analysis, archival tissues, and next-generation sequencing.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »